A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in pat...
Publications
2 shownEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in ...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,160
- Institution
- University of Cape Town
External Links
Identifiers
- ORCID
- 0000-0003-3965-5912
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.